Recent discoveries at CCR are enabling more precise diagnoses and suggest potential new treatment strategies for increasingly specific subsets of patients with lymphoma. Chimeric antigen receptor (CAR) T cells are being used to target new tumor markers in children and young adults with acute leukemias and lymphomas. An adjusted chemotherapy regimen provides a less toxic treatment option for adults with Burkitt lymphoma, a rare, highly aggressive cancer that arises in a class of immune cells known as B cells. We invite you to meet some of our principal investigators conducting research on these diseases.
